NextCure, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXTC research report →
Range $20 – $20
Price Chart
About the company
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function.
- CEO
- Michael S. Richman
- IPO
- 2019
- Employees
- 40
- HQ
- Beltsville, MD, US
Get TickerSpark's AI analysis on NXTC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $22.79M
- P/E
- -0.60
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 2.76
- EV/EBITDA
- -0.28
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -175.46%
- ROIC
- -259.91%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-2,185,000+0.0%
- Op Income
- $-57,616,000
- Net Income
- $-55,844,000-0.3%
- EPS
- $-19.65+17.7%
- OCF Growth
- -21.6%
- FCF Growth
- -20.2%
- 52W High
- $15.74
- 52W Low
- $1.55
- 50D MA
- $4.09
- 200D MA
- $9.29
- Beta
- 1.27
- RSI (14)
- 53
- Avg Volume
- 2.20M
No earnings-call transcripts are available for NXTC yet.
- Free Float
- 62.6%
- Shares Outstanding
- 3.61M
- Float Shares
- 2.26M
of shares held by institutions
24 13F filers
Buy/sell ratio 13.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 91.91K | ▲ 23.93K |
Held by 21 ETFs
Biggest fund positions in NXTC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 10, 26 | Simcere Zaiming, Inc. | sell | 30,000 |
| Jul 31, 26 | ADAR1 Capital Management, LLC | buy | 8,003 |
| Jul 31, 26 | ADAR1 Capital Management, LLC | buy | 25,000 |
| Jul 31, 26 | ADAR1 Capital Management, LLC | buy | 3,300 |
| Jul 30, 26 | ADAR1 Capital Management, LLC | buy | 77,850 |
| Jul 30, 26 | ADAR1 Capital Management, LLC | buy | 100,000 |
| Jul 30, 26 | ADAR1 Capital Management, LLC | buy | 25,000 |
| Jul 30, 26 | ADAR1 Capital Management, LLC | buy | 20,000 |
| Jul 30, 26 | ADAR1 Capital Management, LLC | buy | 20,000 |
| Jul 30, 26 | ADAR1 Capital Management, LLC | buy | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NXTC coverage
Recent articles, reports, and earnings notes.
No research on NXTC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NXTC report →Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
prnewswire.com · Aug 10
NextCure, Inc. (NASDAQ:NXTC) Sees Large Increase in Short Interest
defenseworld.net · Jul 27
Halper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders
prnewswire.com · Jul 24
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—VEEE, NXTC, TCBK, and FHB
globenewswire.com · Jul 23
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB
gurufocus.com · Jul 22
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
prnewswire.com · Jul 21
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBX, and FHB
globenewswire.com · Jul 21
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders
globenewswire.com · Jul 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.